(24/7 MARKET NEWS) – Freeline Therapeutics Holdings plc (NASDAQ: FRLN) announced, this morning, positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease. Results include robust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201, normalization of leukocyte GCase in both patients demonstrates cellular uptake from plasma, and FLT201 has been well tolerated, with no serious adverse events
Freeline is trading at $5.12, up $1.36 (+36.17%), on 2.66M premarket shares traded.
Its 52-week range is $2.11 to $12.00. We actually caught this very early in this morning’s move, but were dealing with technical issues and are just now able to cover the news. It hit a premarket high of 7.25 and, despite the pullback, it’s trading well above its two-month high. It may still attempt to challenge this morning’s high and its July price spikes.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.